2. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002–10 June 2002. Hepatology 2002; 36: S3–S20.
3. Esteban, JI, Sauleda, S, Quer, J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology 2008; 48: 148–162.
4. Thorpe, LE, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology 2002; 155: 645–653.
5. Hahn, JA, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Journal of Infectious Diseases 2002; 186: 1558–1564.
6. Thiede, H, et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug and Alcohol Dependence 2007; 91: S39–S47.
7. van den Berg, CHSB, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of injection drug users. European Journal of Epidemiology 2007; 22: 183–193.
8. Garfein, RS, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health 1996; 86: 655–661.
9. Miller, CL, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737–742.
10. Crofts, N, et al. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology and Community Health 1997; 51: 692–697.
11. Oliveira, ML, et al. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Brazilian Journal of Medical and Biological Research 1999; 32: 1107–1114.
13. MacDonald, MA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Collaboration of Australian NSPs. Medical Journal of Australia 2000; 172: 57–61.
14. Des Jarlais, DC, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS 2005; 19: S20–S255.
15. Muga, R, et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987–2001. Drug and Alcohol Dependence 2006; 82: S29–S33.
16. Tseng, F, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007; 46: 666–671.
17. Burt, RD, et al. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18–30 years, 1994–2004. Journal of Urban Health 2007; 84: 436–454.
18. Simmonds, P, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of NS-5 region. Journal of General Virology 1993; 74: 2391–2399.
19. Simmonds, P. Genetic diversity and evolution of hepatitis C virus-15 years on. Journal of General Virology 2004; 85: 3173–3188.
20. Oliveira, ML, et al. Distribution of HCV genotypes among different exposure categories in Brazil. Brazilian Journal of Medical and Biological Research 1999; 32: 279–282.
21. Oliveira, ML, et al. ‘The first shot’: the context of first injection of illicit drugs, ongoing injecting practices, and hepatitis C infection in Rio de Janeiro, Brazil. Cadernos de Saúde Pública 2006; 22: 861–870.
22. Des Jarlais, DC, et al. WHO Phase II Drug Injection Collaborative Study Group. Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II. BMC Public Health 2006; 2(6): 54.
23. World Health Organization. Programme on substance abuse – Multi-city Study on Drug Injecting and Risk of HIV Infection. A report prepared on behalf of the WHO International Collaborative Group. Geneva, 1994.
24. de Oliveira, JM, et al. Differences in HCV antibody patterns in haemodialysis patients infected with the same virus isolate. Journal of Medical Virology 2001; 63: 265–270.
25. Chen, Z, Weck, K. Hepatitis C virus genotyping: interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b, Journal of Clinical Microbiology 2002; 40: 3127–3134.
26. Kuiken, C, et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 2006; 44: 1355–1361.
27. Tamura, K, et al. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Molecular Biology and Evolution 2007; 24: 1596–1599.
28. Saitou, N, Nei, M. The neighbour-joining method: a new method for reconstructing phylogenetic trees. Molecular Biology and Evolution 1987; 4: 406–425.
29. Felsenstein, J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39: 783–791.
30. Tamura, K, et al. Prospects for inferring very large phylogenies by using the neighbour-joining method. Proceedings of the National Academy of Sciences USA 2004; 101: 11030–11035.
31. Stark, K, et al. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. International Journal of Epidemiology 1997; 26: 1359–1366.
32. Stark, K, et al. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiology and Infection 2006; 134: 814–819.
33. Strathdee, SA, Patterson, TL. Behavioral interventions for HIV-positive and HCV-positive drug users. AIDS and Behavior 2006; 10: 115–130.
34. Roy, K, et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiology and Infection 2007; 135: 433–442.
35. Bastos, FI, et al. Is human immunodeficiency virus/acquired immunodeficiency syndrome decreasing among Brazilian injection drug users? Recent findings and how to interpret them. Memórias do Instituto Oswaldo Cruz 2005; 100: 91–96.
36. Buxton, MB, et al. Association between injection practices and duration of injection among recently initiated injection drug users. Drug and Alcohol Dependence 2004; 75: 177–183.
37. Lucidarme, D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology and Infection 2004; 132: 699–708.
38. Pybus, OG, et al. The hepatitis C virus epidemic among injecting drug users. Infection, Genetics and Evolution 2005; 5: 131–139.
39. Matheï, C, et al. The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium. Journal of Viral Hepatitis 2008; 15: 399–408.
40. Hacker, MA, et al. The role of ‘long-term’ and ‘new’ injectors in a declining HIV/AIDS epidemic in Rio de Janeiro, Brazil. Substance Use & Misuse 2005; 40: 99–123.